دورية أكاديمية
Characterization of (2R, 3S)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme
| العنوان: | Characterization of (2R, 3S)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme |
|---|---|
| المؤلفون: | Zhang, Yuhua yzhang@wyeth.com, Hegen, Martin1, Xu, Jun2, Keith, James C.1, Jin, Guixian2, Du, Xuemei2, Cummons, Terri2, Sheppard, Barbara J.1, Sun, LinHong1, Zhu, Yi1, Rao, Vikram R.1, Wang, Qin1, Xu, Weixin1, Cowling, Rebecca2, Nickerson-Nutter, Cheryl L.1, Gibbons, Jay2, Skotnicki, Jerry2, Lin, Lih-Ling1, Levin, Jeremy2 |
| المصدر: | International Immunopharmacology. Dec2004, Vol. 4 Issue 14, p1845-1857. 13p. |
| مصطلحات موضوعية: | *TUMOR necrosis factors, *MACROPHAGES, *ENZYMES, *CONNECTIVE tissues, *IMMUNOLOGIC diseases, *MICE |
| مستخلص: | TNF-α converting enzyme (TACE) is a validated therapeutic target for the development of oral tumor necrosis factor-α (TNF-α) inhibitors. Here we report the pre-clinical results and characterization of a selective and potent TACE inhibitor, (2R, 3S)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide (TMI-2), in various in vitro and in vivo assays. TMI-2 is a potent TACE inhibitor in an enzymatic FRET assay (IC50=2 nM). It is more than 250-fold selective over MMP-1, -7, -9, -14, and ADAM-10 in vitro. In cell-based assays and human whole blood, TMI-2 inhibits lipopolysaccharide (LPS)-induced TNF secretion with IC50s<1 uM. Importantly, TMI-2 inhibits the spontaneous release of TNF-α in human synovium tissue explants of rheumatoid arthritis patients with an IC50 of 0.8 μM. In vivo, TMI-2 potently inhibits LPS-induced TNF-α production in mice (ED50=3 mg/kg). In the adjuvant-induced arthritis (AIA) model in rats, treatment with TMI-2 at 30 mg/kg and 100 mg/kg p.o. b.i.d. was highly effective in reducing joint arthritis scores. In a semi-therapeutic collagen-induced arthritis (CIA) model in mice, TMI-2 is highly effective in reducing disease severity scores after oral treatment at 100 mg/kg twice per day. In summary, TMI-2 is a potent and selective TACE inhibitor that inhibits TNF-α production and reduces the arthritis scores in pre-clinical models. TMI-2 represents a novel class of TACE inhibitors that may be effective and beneficial in the treatment of rheumatoid arthritis as well as other TNF-mediated inflammatory autoimmune diseases. [Copyright &y& Elsevier] |
| قاعدة البيانات: | Academic Search Index |
| ResultId |
1 |
|---|---|
| Header |
asx Academic Search Index 14957955 1202 6 Academic Journal academicJournal 1202.07653808594 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=14957955&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Characterization of (2R, 3S)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Zhang%2C+Yuhua%22">Zhang, Yuhua</searchLink><i> yzhang@wyeth.com</i><br /><searchLink fieldCode="AR" term="%22Hegen%2C+Martin%22">Hegen, Martin</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Xu%2C+Jun%22">Xu, Jun</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Keith%2C+James+C%2E%22">Keith, James C.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Jin%2C+Guixian%22">Jin, Guixian</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Du%2C+Xuemei%22">Du, Xuemei</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Cummons%2C+Terri%22">Cummons, Terri</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Sheppard%2C+Barbara+J%2E%22">Sheppard, Barbara J.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Sun%2C+LinHong%22">Sun, LinHong</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Zhu%2C+Yi%22">Zhu, Yi</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Rao%2C+Vikram+R%2E%22">Rao, Vikram R.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Wang%2C+Qin%22">Wang, Qin</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Xu%2C+Weixin%22">Xu, Weixin</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Cowling%2C+Rebecca%22">Cowling, Rebecca</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Nickerson-Nutter%2C+Cheryl+L%2E%22">Nickerson-Nutter, Cheryl L.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Gibbons%2C+Jay%22">Gibbons, Jay</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Skotnicki%2C+Jerry%22">Skotnicki, Jerry</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Lin%2C+Lih-Ling%22">Lin, Lih-Ling</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Levin%2C+Jeremy%22">Levin, Jeremy</searchLink><relatesTo>2</relatesTo> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <searchLink fieldCode="JN" term="%22International+Immunopharmacology%22">International Immunopharmacology</searchLink>. Dec2004, Vol. 4 Issue 14, p1845-1857. 13p. ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => *<searchLink fieldCode="DE" term="%22TUMOR+necrosis+factors%22">TUMOR necrosis factors</searchLink><br />*<searchLink fieldCode="DE" term="%22MACROPHAGES%22">MACROPHAGES</searchLink><br />*<searchLink fieldCode="DE" term="%22ENZYMES%22">ENZYMES</searchLink><br />*<searchLink fieldCode="DE" term="%22CONNECTIVE+tissues%22">CONNECTIVE tissues</searchLink><br />*<searchLink fieldCode="DE" term="%22IMMUNOLOGIC+diseases%22">IMMUNOLOGIC diseases</searchLink><br />*<searchLink fieldCode="DE" term="%22MICE%22">MICE</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => TNF-α converting enzyme (TACE) is a validated therapeutic target for the development of oral tumor necrosis factor-α (TNF-α) inhibitors. Here we report the pre-clinical results and characterization of a selective and potent TACE inhibitor, (2R, 3S)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide (TMI-2), in various in vitro and in vivo assays. TMI-2 is a potent TACE inhibitor in an enzymatic FRET assay (IC50=2 nM). It is more than 250-fold selective over MMP-1, -7, -9, -14, and ADAM-10 in vitro. In cell-based assays and human whole blood, TMI-2 inhibits lipopolysaccharide (LPS)-induced TNF secretion with IC50s<1 uM. Importantly, TMI-2 inhibits the spontaneous release of TNF-α in human synovium tissue explants of rheumatoid arthritis patients with an IC50 of 0.8 μM. In vivo, TMI-2 potently inhibits LPS-induced TNF-α production in mice (ED50=3 mg/kg). In the adjuvant-induced arthritis (AIA) model in rats, treatment with TMI-2 at 30 mg/kg and 100 mg/kg p.o. b.i.d. was highly effective in reducing joint arthritis scores. In a semi-therapeutic collagen-induced arthritis (CIA) model in mice, TMI-2 is highly effective in reducing disease severity scores after oral treatment at 100 mg/kg twice per day. In summary, TMI-2 is a potent and selective TACE inhibitor that inhibits TNF-α production and reduces the arthritis scores in pre-clinical models. TMI-2 represents a novel class of TACE inhibitors that may be effective and beneficial in the treatment of rheumatoid arthritis as well as other TNF-mediated inflammatory autoimmune diseases. [Copyright &y& Elsevier] ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1016/j.intimp.2004.08.003
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 13
[StartPage] => 1845
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => TUMOR necrosis factors
[Type] => general
)
[1] => Array
(
[SubjectFull] => MACROPHAGES
[Type] => general
)
[2] => Array
(
[SubjectFull] => ENZYMES
[Type] => general
)
[3] => Array
(
[SubjectFull] => CONNECTIVE tissues
[Type] => general
)
[4] => Array
(
[SubjectFull] => IMMUNOLOGIC diseases
[Type] => general
)
[5] => Array
(
[SubjectFull] => MICE
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Characterization of (2R, 3S)-2-({[4-(2-butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-α converting enzyme
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Zhang, Yuhua
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hegen, Martin
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Xu, Jun
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Keith, James C.
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jin, Guixian
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Du, Xuemei
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cummons, Terri
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sheppard, Barbara J.
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sun, LinHong
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Zhu, Yi
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Rao, Vikram R.
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Wang, Qin
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Xu, Weixin
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cowling, Rebecca
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Nickerson-Nutter, Cheryl L.
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gibbons, Jay
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Skotnicki, Jerry
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lin, Lih-Ling
)
)
)
[18] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Levin, Jeremy
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 20
[M] => 12
[Text] => Dec2004
[Type] => published
[Y] => 2004
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 15675769
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 4
)
[1] => Array
(
[Type] => issue
[Value] => 14
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => International Immunopharmacology
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |